In the ‘First Workshop on Pharmacology and Management of Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i): Consensus about Concomitant Medications’, promoted by the Spanish Breast Cancer Cooperative Group SOLTI, medical oncologists specialized in breast cancer joined physicians specialized in pharmacology, cardiology, psychiatry, infectious diseases, palliative care or radiation oncology in an interdisciplinary discussion forum, at Spanish national level, to address different issues regarding patients treated with palbociclib and ribociclib. These issues included overall management of adverse events (AEs) of special interest, expert opinion about clinical situations for which evidence of treatment with these drugs is limited, and, above all, concomitant medications that may be safely administered. This workshop was held on 22 May 2018. This article brings together the issues that were addressed, the information compiled and the conclusions of this 1-day meeting.

中文翻译：

---

Palbociclib和ribociclib在乳腺癌中：伴随用药管理共识研讨会

在西班牙乳腺癌合作组织SOLTI倡导的“首个细胞周期蛋白依赖性激酶（CDK）4/6抑制剂（CDK4 / 6i）药理学和管理研讨会上：伴随药物的共识”中，专门从事乳腺癌的医学肿瘤学家参加了会议。在西班牙国家一级的跨学科讨论论坛上，专门研究药理学，心脏病学，精神病学，传染病，姑息治疗或放射肿瘤学的医师，以解决有关用palbociclib和ribociclib治疗的患者的不同问题。这些问题包括特别关注的不良事件（AE）的整体管理，对这些药物治疗证据有限的临床情况的专家意见，以及最重要的是可以安全使用的伴随药物。该研讨会于2018年5月22日举行。